Plus Therapeutics Discloses Substantial 2025 Executive Compensation, CEO Totaling $5.56M

summarizeSummary

Plus Therapeutics disclosed its 2025 executive compensation, revealing a significant increase for its CEO and CFO, with the CEO's total compensation reaching $5.56 million.

check_boxKey Events

• Executive Compensation Approved

  The Compensation Committee approved discretionary cash bonuses for Named Executive Officers for Fiscal Year 2025 on February 9, 2026.

• CEO Compensation Details

  President and CEO Marc H. Hedrick's total compensation for 2025 was $5,566,732, a substantial increase from $1,260,285 in 2024, primarily driven by option and restricted stock awards.

• CFO Compensation Details

  CFO Andrew Sims' total compensation for 2025 was $1,631,279, up from $621,116 in 2024.

• Context of Prior Disclosure

  This disclosure finalizes compensation figures that were previously noted as undetermined in the company's S-1 registration statement filed on January 9, 2026.

auto_awesomeAnalysis

This 8-K filing reveals the final 2025 compensation for Plus Therapeutics' Named Executive Officers, which was previously pending as noted in the S-1 registration statement filed on January 9, 2026. The disclosed figures show a substantial increase in total compensation for both the CEO and CFO, with the CEO's package reaching $5.56 million. This significant compensation, particularly the large equity awards, comes shortly after the company completed a dilutive public offering in mid-January, raising approximately $13.3 million in net proceeds. Investors may scrutinize the magnitude of executive compensation relative to the company's market capitalization and recent capital-raising activities, potentially raising concerns about shareholder value and capital allocation.